CEO Update | 24 April 2023

Q1 Finance Report

Today we’ve published our latest quarterly data on sector financing. The first quarter of 2023 has seen deal flow continue for the UK’s innovative life science and biotech companies at all stages of development. Despite global macroeconomic headwinds, suppressed public markets and political uncertainty weighing on investor confidence, venture investment remained steady, with private UK biotechs securing £258 million across 20 deals, with an average deal size of £13 million. Read our press release for more details

USIT guide

A new guide that aims to speed up the development, maturity and scale-up of the University spin-out process is launched today – and it’s a process we are proud to endorse and support. The University Spin-out Investment Terms (USIT) Guide has been developed by prominent venture capital investors and leading universities, and “identifies a landing zone” for what a positive deal could and should look like.

I’m attending the launch at the Chancellor’s Hall, Senate House, University of London this evening. The work on the document has been led by the TenU group and funded by Research England. TenU members are the technology transfer offices of the University of Cambridge, Columbia University, University of Edinburgh, Imperial College London, KU Leuven, University of Manchester, MIT, University of Oxford, Stanford University, and UCL all aiming to increase the societal impact of research.

I encourage members to engage with this new best practice guide and welcome any feedback. It demonstrates that there is a shared commitment across both the investor and university communities to work together to build businesses that can change the world. I hope this initiative will speed up the development, maturity and scale-up of spin-out, generating more jobs and productivity.

VPAS

The formal negotiations on the upcoming VPAS scheme have not started and already there is already a row about the process. The British Generics Assoocation have chosen to seek a judicial review of the process of government and industry engagement. The ABPI has commented on that development. Not the easiest first month for the new government appointed negotiator Sir Hugh Taylor. I’m keeping a close interest in this and welcome member insight.

Sector response on LIFTs

This week we are working closely with members, under the leadership of Dan Mahoney in his role as the UK Life Science Investment Envoy to produce a consolidated sector response on the Long-term Investment For Technology and Science (LIFTS) initiative from the government. The initiative aims to establish new investment vehicles to crowd-in investment from institutional investors, particularly defined contribution (DC) pension funds, to the UK’s most innovative science and technology companies. This week is an important staging post on a long-term agenda on which I hope we’ll see real movement in the coming months

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion

Grey Wolf Therapeutics closes oversubscribed $50 million Series B Financing Expansion, led by ICG Life Sciences, to accelerate and expand first-of-its-kind antigen modulation technology. This brings the total Series B funds raised to nearly $100 million.

Somnus Scientific announces partnership with Life Science Group and Creonate

Somnus Scientific has agreed a collaborative partnership with Life Science Group (LSG) and Creonate Manufacturing for the next phase of product development.

Coulter Partners DEI: Views from leadership series - Ankit Mahadevia

In the latest instalment of its Diversity, Equity & Inclusion Leadership series, Coulter Partners spoke to Ankit Mahadevia, MD, Founder and Chair of Spero Therapeutics, and author of 'Quiet Leader, Loud Results'.

Discovery Park: Asymchem secures former Pfizer Sandwich, UK, development

Asymchem will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Ultra-concentrated, ultra-rapid acting insulin demonstrates superiority in Phase I clinical trial in Type 2 diabetics

AT278 demonstrates significantly accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI

More within